0.38
-0.1091(-22.49%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.49 |
| Day High | 0.5 |
| Day Low | 0.35 |
| 52-Week High | 33.66 |
| 52-Week Low | 0.35 |
| Volume | 6.4M |
| Average Volume | 7.3M |
| Market Cap | 10.18M |
| PE | -2.35 |
| EPS | -0.16 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 4.16 |
| Change | -0.11 |
If you invested $1000 in Liminatus Pharma, Inc. Class A Common Stock (LIMN) since IPO date, it would be worth $37.34 as of February 14, 2026 at a share price of $0.376. Whereas If you bought $1000 worth of Liminatus Pharma, Inc. Class A Common Stock (LIMN) shares 6 months ago, it would be worth $91.26 as of February 14, 2026 at a share price of $0.376.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
GlobeNewswire Inc.
Oct 30, 2025 2:04 PM GMT
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Underst
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
GlobeNewswire Inc.
Jul 28, 2025 11:30 AM GMT
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic ValueLA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
GlobeNewswire Inc.
Jul 25, 2025 12:31 PM GMT
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committedLA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a pre